Trueblood Wealth Management’s Perspective Therapeutics CATX Stock Holding History

Trueblood Wealth Management’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$340K	Buy	99,740 +679	+0.7%	+$2.56K	0.12%	195
2026 Q1	$413K	Sell	99,061 -20,000	-17%	-$84.5K	0.16%	165
2025 Q4	$327K	Buy	119,061 +50,000	+72%	+$143K	0.13%	190
2025 Q3	$237K	Hold	69,061	–	–	0.09%	226
2025 Q2	$238K	Buy	69,061 +46,825	+211%	+$124K	0.1%	222
2025 Q1	$47.4K	Hold	22,236	–	–	0.02%	234
2024 Q4	$70.9K	Buy	22,236 +6,000	+37%	+$49K	0.04%	225
2024 Q3	$217K	Buy	+16,236	New	+$216K	0.11%	216

Other funds holding CATX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Trueblood Wealth Management's CATX Position: Q2 2026 in Review

Trueblood Wealth Management increased its Perspective Therapeutics (CATX) stake by 0.69% in Q2 2026, buying an estimated $2.56K and bringing the position to 99,740 shares worth $340K. The position accounts for 0.12% of the portfolio, ranked #195.

Trueblood Wealth Management first reported a position in CATX in Q3 2024 and has held it in 8 quarters since. The position peaked at $413K in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

Trueblood Wealth Management held 99,740 shares of Perspective Therapeutics worth $340K as of Q2 2026.
Trueblood Wealth Management bought 679 Perspective Therapeutics shares in Q2 2026, an estimated $2.56K.
Perspective Therapeutics made up 0.12% of Trueblood Wealth Management's portfolio in Q2 2026, its #195 holding.
Trueblood Wealth Management first reported a position in Perspective Therapeutics in Q3 2024 and has held it in 8 quarters since.
Trueblood Wealth Management's Perspective Therapeutics position peaked at $413K in Q1 2026.
132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Trueblood Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.